The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers

2012 ◽  
Vol 16 (1) ◽  
pp. 15-15
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychosocial Intervention

scholarly journals Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY)

BMJ ◽  
2012 ◽  
Vol 345 (jul17 1) ◽  
pp. e4693-e4693 ◽  
Author(s):  
F. B. Waldorff ◽  
D. V. Buss ◽  
A. Eckermann ◽  
M. L. H. Rasmussen ◽  
N. Keiding ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychosocial Intervention ◽  
Intervention Study

scholarly journals Early psychosocial intervention in Alzheimer's disease: cost utility evaluation alongside the Danish Alzheimer's Intervention Study (DAISY)

BMJ Open ◽  
2014 ◽  
Vol 4 (1) ◽  
pp. e004105 ◽  
Author(s):  
Rikke Søgaard ◽  
Jan Sørensen ◽  
Frans B Waldorff ◽  
Ane Eckermann ◽  
Dorte V Buss ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychosocial Intervention ◽  
Intervention Study ◽  
Cost Utility ◽  
Disease Cost ◽  
Utility Evaluation

Cost Analysis of Early Psychosocial Intervention in Alzheimer's Disease

2014 ◽  
Vol 37 (3-4) ◽  
pp. 141-153 ◽  
Author(s):  
Rikke Søgaard ◽  
Jan Sørensen ◽  
Frans B. Waldorff ◽  
Ane Eckermann ◽  
Dorthe V. Buss ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Analysis ◽  
Psychosocial Intervention

scholarly journals Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial

2015 ◽  
Vol 27 (12) ◽  
pp. 2059-2067 ◽  
Author(s):  
Paul B. Rosenberg ◽  
Lea T. Drye ◽  
Anton P. Porsteinsson ◽  
Bruce G. Pollock ◽  
D.P. Devanand ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychosocial Intervention ◽  
Rating Scale ◽  
Controlled Trial ◽  
Placebo Response ◽  
Regression To The Mean ◽  
Recent Trial ◽  
Major Predictor ◽  
Global Impression Of Change

ABSTRACTBackground:Placebo responses raise significant challenges for the design of clinical trials. We report changes in agitation outcomes in the placebo arm of a recent trial of citalopram for agitation in Alzheimer's disease (CitAD).Methods:In the CitAD study, all participants and caregivers received a psychosocial intervention and 92 were assigned to placebo for nine weeks. Outcomes included Neurobehavioral Rating Scale agitation subscale (NBRS-A), modified AD Cooperative Study-Clinical Global Impression of Change (CGIC), Cohen-Mansfield Agitation Inventory (CMAI), the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (NPI A/A) and Total (NPI-Total) and ADLs. Continuous outcomes were analyzed with mixed-effects modeling and dichotomous outcomes with logistic regression.Results:Agitation outcomes improved over nine weeks: NBRS-A mean (SD) decreased from 7.8 (3.0) at baseline to 5.4 (3.2), CMAI from 28.7 (6.7) to 26.7 (7.4), NPI A/A from 8.0 (2.4) to 4.9 (3.8), and NPI-Total from 37.3 (17.7) to 28.4 (22.1). The proportion of CGI-C agitation responders ranged from 21 to 29% and was significantly different from zero. MMSE improved from 14.4 (6.9) to 15.7 (7.2) and ADLs similarly improved. Most of the improvement was observed by three weeks and was sustained through nine weeks. The major predictor of improvement in each agitation measure was a higher baseline score in that measure.Conclusions:We observed significant placebo response which may be due to regression to the mean, response to a psychosocial intervention, natural course of symptoms, or nonspecific benefits of participation in a trial.

Sign in / Sign up

Export Citation Format

Share Document